Free shipping on all orders over $ 500

Etaracizumab

Cat. No. M25268
Etaracizumab Structure
Synonym:

LM 609; MEDI 523; Anti-αvβ3 Integrin Recombinant Antibody

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Etaracizumab (LM 609) is an αvβ3 integrin IgG1 monoclonal antibody. Etaracizumab inhibits angiogenesis and melanoma tumor growth. Etaracizumab can be used to research anticancer.

Chemical Information
CAS Number 892553-42-3
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Stergios J Moschos, et al. J Immunother. Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma

[2] Peter Hersey, et al. Cancer. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma

[3] Tae Jin Kim, et al. Cancer Biol Ther. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer

[4] Charles N Landen, et al. Neoplasia. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer

[5] Catherine Delbaldo, et al. Invest New Drugs. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors

Related Integrin Products
HSDVHK-NH2

HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM).

LDV

LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC.

Cyclo(RADfK)

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.

Obtustatin

Obtustatin is a non-RGD disintegrin of 41 residues.

Integrin Binding Peptide

Integrin Binding Peptide is derived by fibronectin.

  Catalog
Abmole Inhibitor Catalog




Keywords: Etaracizumab, LM 609; MEDI 523; Anti-αvβ3 Integrin Recombinant Antibody supplier, Integrin, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.